Back to top
more

Apollo Endosurgery, Inc. (APEN)

(Delayed Data from NSDQ)

$3.54 USD

3.54
5,491

-0.28 (-7.33%)

Updated May 3, 2019 04:13 PM ET

After-Market: $3.95 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Boston Scientific's (BSX) New Buyout to Expand Global Presence

by Zacks Equity Research

Boston Scientific's (BSX) new acquisition deal is expected to strengthen the company's presence in China.

Boston Scientific's (BSX) New Buyout to Expand its Portfolio

by Zacks Equity Research

Boston Scientific's (BSX) latest buyout is expected to boost its Endoscopy business by adding Apollo Endosurgery's product portfolio, which includes devices used during ELS procedures.

Apollo Endosurgery, Inc. (APEN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of -33.33% and 8.95%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Apollo Endosurgery, Inc. (APEN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of -23.81% and 7.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Treace Medical Concepts (TMCI) Moves 8.2% Higher: Will This Strength Last?

by Zacks Equity Research

Treace Medical Concepts (TMCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Apollo Endosurgery, Inc. (APEN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of 0% and 6.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Inari Medical, Inc. (NARI): Can Its 6.2% Jump Turn into More Strength?

by Zacks Equity Research

Inari Medical, Inc. (NARI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Apollo Endosurgery, Inc. (APEN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of -35% and 0.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

SARTORIUS (SARTF) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

SARTORIUS (SARTF) delivered earnings and revenue surprises of 1.24% and 1.82%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Apollo Endosurgery, Inc. (APEN) Q4 Earnings Expected to Decline

by Zacks Equity Research

Apollo Endosurgery, Inc. (APEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Boston Scientific (BSX) Hit by Procedure Deferrals Amid COVID

by Zacks Equity Research

Although Boston Scientific (BSX) reports margin expansion on a year-over-year basis, the decline in R&D expenses is concerning.

Walgreens (WBA), Village MD Plan to Expand Into Arizona

by Zacks Equity Research

Walgreens (WBA) and VillageMD to improve access to overall care for patients with chronic conditions by opening eight new Village Medical at Walgreens primary care practices in the Tucson area.

Zimmer Biomet's (ZBH) Pandemic Recovery Slow, Margin Woes Stay

by Zacks Equity Research

The third quarter brings greater COVID-related pressure than expected for Zimmer Biomet (ZBH).

Here's Why You Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS' (STE) strong segmental performance and bullish 2022 outlook.

Here's Why You Should Retain Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors are optimistic about Chemed (CHE), given impressive performance of the Roto-Rooter arm and solid growth in VITAS admissions.

Here's Why You Should Hold SmileDirectClub (SDC) Stock for Now

by Zacks Equity Research

Investors are optimistic about SmileDirectClub (SDC), backed by its expansion in the teledentistry space and the long-term growth target.

Abiomed (ABMD) Reports Positive Data Backing preCARDIA System

by Zacks Equity Research

Abiomed's (ABMD) preCARDIA system has proven to be effective in reducing cardiac filling pressures and increasing urine output in ADHF patients.

Alcon's (ALC) Global Growth Solid, New Lenses Sales Rise

by Zacks Equity Research

Alcon's (ALC) new contact lenses are gaining market share and the Systane brand family has been posting strong double-digit growth in all regions.

Quest Diagnostics (DGX) Expands Extended Care With New Buyout

by Zacks Equity Research

This latest acquisition builds on Quest Diagnostics' (DGX) 2018 acquisition of Mobile Medical Examination Service (MedXM), a provider of home-based health risk assessments and related services.

Abbott's (ABT) Organic Base Sales Grow Amid COVID Case Surge

by Zacks Equity Research

Even though COVID-19 case rates are surging, Abbott (ABT) is registering growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.

PacBio (PACB) to Leverage Google's Deep Learning Technologies

by Zacks Equity Research

PacBio's (PACB) research collaboration with Google will likely enhance its HiFi Sequencing technology to extract greater value from genomic data.

Here's Why You Should Invest in Neogen (NEOG) Stock Now

by Zacks Equity Research

Neogen's (NEOG) better-than-expected Q2 revenues and robust growth across Food Safety & Animal Safety businesses instill investor confidence.

Here's Why You Should Hold on to Walgreens Boots (WBA) for Now

by Zacks Equity Research

Investors are optimistic about Walgreens Boots' (WBA) robust growth in the International segment and strong first-quarter fiscal 2022 results.

QIAGEN (QGEN) to Boost Testing Capacity With Liquid-Based Kit

by Zacks Equity Research

QIAGEN's (QGEN) artus SARS-CoV-2 Prep&Amp UM is faster than standard processes and can spot the virus more reliably, including the new Omicron variant.

IDEXX (IDXX) Collaborates With PetDx for Canine Cancer Test

by Zacks Equity Research

Following the partnership between IDEXX (IDXX) and PetDx , the test is likely to be available later in January to all veterinary customers of IDXX in the United States and Canada.